Switch theme
Sign up to access all valuation multiples
Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets.
1973
n/a
LTM Revenue $1.2B
LTM EBITDA $240M
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hanmi Pharm has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $240M.
In the most recent fiscal year, Hanmi Pharm achieved revenue of $1.1B and an EBITDA of $217M.
Hanmi Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hanmi Pharm valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $633M | XXX | $605M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $240M | XXX | $217M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $170M | XXX | $160M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $115M | XXX | $89.8M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $219M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Hanmi Pharm's stock price is KRW 287000 (or $212).
Hanmi Pharm has current market cap of KRW 3.64T (or $2.7B), and EV of KRW 3.89T (or $2.9B).
See Hanmi Pharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $2.7B | XXX | XXX | XXX | XXX | $8.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Hanmi Pharm has market cap of $2.7B and EV of $2.9B.
Hanmi Pharm's trades at 2.6x EV/Revenue multiple, and 13.3x EV/EBITDA.
Equity research analysts estimate Hanmi Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hanmi Pharm has a P/E ratio of 23.5x.
See valuation multiples for Hanmi Pharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 12.0x | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBIT | 16.9x | XXX | 18.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.5x | XXX | 30.0x | XXX | XXX | XXX |
| EV/FCF | 20.8x | XXX | 29.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHanmi Pharm's last 12 month revenue growth is 8%
Hanmi Pharm's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hanmi Pharm's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hanmi Pharm's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hanmi Pharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hanmi Pharm acquired XXX companies to date.
Last acquisition by Hanmi Pharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Hanmi Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hanmi Pharm founded? | Hanmi Pharm was founded in 1973. |
| Where is Hanmi Pharm headquartered? | Hanmi Pharm is headquartered in South Korea. |
| Who is the CEO of Hanmi Pharm? | Hanmi Pharm's CEO is Mr. Jae-Hyeon Park. |
| Is Hanmi Pharm publicy listed? | Yes, Hanmi Pharm is a public company listed on KRX. |
| What is the stock symbol of Hanmi Pharm? | Hanmi Pharm trades under 128940 ticker. |
| When did Hanmi Pharm go public? | Hanmi Pharm went public in 2010. |
| Who are competitors of Hanmi Pharm? | Similar companies to Hanmi Pharm include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hanmi Pharm? | Hanmi Pharm's current market cap is $2.7B |
| What is the current revenue of Hanmi Pharm? | Hanmi Pharm's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Hanmi Pharm? | Hanmi Pharm revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Hanmi Pharm? | Current revenue multiple of Hanmi Pharm is 2.5x. |
| Is Hanmi Pharm profitable? | Yes, Hanmi Pharm is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hanmi Pharm? | Hanmi Pharm's last 12 months EBITDA is $240M. |
| What is Hanmi Pharm's EBITDA margin? | Hanmi Pharm's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Hanmi Pharm? | Current EBITDA multiple of Hanmi Pharm is 12.0x. |
| What is the current FCF of Hanmi Pharm? | Hanmi Pharm's last 12 months FCF is $138M. |
| What is Hanmi Pharm's FCF margin? | Hanmi Pharm's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Hanmi Pharm? | Current FCF multiple of Hanmi Pharm is 20.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
